Nuformix Share Discussion Threads

[sentiment riles] 04/11/2021 09:17

This will be better than sng

[sentiment riles] 04/11/2021 09:16

Were you speaking about me bc? Had not read the posts. Was just commenting 😂

[david gruen] 04/11/2021 09:14

Imagine if this did an SNG :-)

[bc4] 04/11/2021 09:05

Well at least the idiots know who they ARE. HA HA HA

[sentiment riles] 04/11/2021 09:00

bc4 the hindsight king has arrived

[jaforsadi] 04/11/2021 08:54

Dnt buy junk

[parsons4] 04/11/2021 08:43

What a terrible place this is, just looked to see if there was any sensible discussion but no !!! not at all. Still I will hang on to my relatively small holding because things seem to be looking up, and financing does not seem to be a short term problem.

[bobby semen] 03/11/2021 19:22

#inhismind


#24/7



#tooooooosatisfying




#lOLOLOLOLOLOLOLOLOLOLOL

[sentiment riles] 03/11/2021 19:07

telbap - 15 Nov 2019 - 11:38:42 - 4722 of 30758
Ameretto = Sentiment rules mkII.

Engage at your own risk.

Read back the posts he/she has made
..............
....good auld HUR - at your peril alright. Read back now

😂

[sentiment riles] 03/11/2021 18:59

Am you must be still angry about HUR when 61p

[soupdragon55] 03/11/2021 18:41

Cash runway to end of 2022, prior to recent NXP001 global licence. Any success on NXP004 will see it licenced pretty quick. No need for placing.

[sentiment riles] 03/11/2021 18:17

Vote of long term confidence. Not a play or desperation placing

[sentiment riles] 03/11/2021 18:15

Cash runway needs sorting. Backed by funds filling a placement. This is one of those rare times an share price will go strataspheric on a placing RNS

[spurs90] 03/11/2021 18:03

Preclinical studies show potential for single agent and combination use. Data from an in vitro IPF model has shown anti-fibrotic/anti-inflammatory activity of NXP002 alone and in combination with two approved IPF drugs. These studies suggest the addition of NXP002 may achieve the same or better activity at lower doses of the approved drugs, which may offer advantages as both have challenging side effects. Additional preclinical studies are planned as Nuformix builds out a more robust data package. Results due Q4 2021
Progress on NXP004. Research is also underway on developing new forms of an undisclosed marketed oncology drug (with sales c.$1.5bn in 2020). Results Due Q4 2021.
A patent filed in 2020 may be granted in 2022.

Licensing deal with Oxilio. A licensing deal has been finalised with Oxilio, a private UK company, for NXP001, a novel formulation of aprepitant intended for cancer treatment.
Under the terms of the licensing agreement, Oxilio has obtained an exclusive licence to research, develop and commercialise NXP001 globally for oncology indications. Nuformix is eligible to receive an undisclosed upfront payment, development milestone payments and a royalty on net sales, capped at £2 million per annum.

Indicative value NXP002
. We believe a licensing deal or partnership for NXP002 as a Phase 1-ready asset for IPF could have a $360-450m headline value, although the upfront would be likely to be in the $10-20m range. Although, the economics of such deals are difficult to predict, the future NPV of this asset alone could be +£50m.
Fully funded
Cash to 2023. Nuformix results show net cash of £1.6m, giving a runway into late CY2022

[sentiment riles] 03/11/2021 17:12

I notice not much to say about SP

That's excellent news

😂